If you have been reading about ipamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
=== "Central pillar" cave structure === In the typical "central pillar" design, pilgrims can circumambulate around a central column incorporating a niche for a statue of the Buddha, which is a representation of the stupa. The so-called "central pillar" which appears on a plan is actually not a pillar at all but only the rock at the back of the cave, into which was bored a circular corridor allowing for circumambulation. A large vaulted chamber is located in front of the "central pillar" column and a smaller rear chamber behind with two tunnel-like corridors on the sides linking these spaces. In the front chamber, a three-dimensional image of Buddha would have been housed in a large niche serving as the focus of the interior, however, none of these sculptures have survived at Kizil. The rear chamber may feature the parinirvana scene in the form of a mural or large sculpture, and in some cases, a combination of both. The "central pillar" layout is possibly related to the structural design of Kara Tepe in northern Bactria. The program of the paintings in the "central pillar" caves generally follows a fixed arrangement: the walls of the main cella show sermons of the Buddha, the ceiling has rhomboid vignettes alluding to Jatakas, the central niche has the scene of the Indrasala Cave. The back room or corridor has scenes related to the Parinirvana, and finally the painting over the exit is related to the Tusita Heaven and the future Buddha Maitreya.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
At the initiation of treatment, GnRH agonists are associated with a "flare" effect on hormone levels due to acute overstimulation of the GnRH receptor. In men, LH levels increase by up to 800%, while testosterone levels increase to about 140 to 200% of baseline. Gradually however, the GnRH receptor desensitizes; testosterone levels peak after about 2 to 4 days, return to baseline after about 7 to 8 days, and are reduced to castrate levels within 2 to 4 weeks. Antigonadotropins such as estrogens and cyproterone acetate as well as nonsteroidal antiandrogens such as flutamide and bicalutamide can be used beforehand and concomitantly to reduce or prevent the effects of the testosterone flare caused by GnRH agonists. In contrast to GnRH agonists, GnRH antagonists, such as degarelix (Firmagon) and elagolix (Orilissa), work by binding to the GnRH receptor without activating it, thereby displacing GnRH from the receptor and preventing its activation. Unlike with GnRH agonists, there is no initial surge effect with GnRH antagonists; the therapeutic effects are immediate, with sex hormone levels being reduced to castrate levels within a few days. GnRH modulators are highly effective for testosterone suppression in transgender women and have few or no side effects when sex hormone deficiency is avoided with concomitant estrogen therapy. However, GnRH modulators tend to be very expensive (typically US$10,000 to US$15,000 per year in the United States), and are often denied by medical insurance.
Bromley forms part of the Bromley and Biggin Hill Parliament constituency. The current MP is Peter Fortune. Thomas Turrell is the London Assembly member for the Bexley and Bromley constituency, in which the town is located. This post was previously held by Fortune. Bromley's most prominent MP was the former Conservative prime minister, Harold Macmillan. Bromley is part of the Bromley Town ward for elections to Bromley London Borough Council.
=== Catabolism === Isoleucine is both a glucogenic and a ketogenic amino acid. After transamination with alpha-ketoglutarate, the carbon skeleton is oxidised and split into propionyl-CoA and acetyl-CoA. Propionyl-CoA is converted into succinyl-CoA, a TCA cycle intermediate which can be converted into oxaloacetate for gluconeogenesis (hence glucogenic). In mammals acetyl-CoA cannot be converted to carbohydrate but can be either fed into the TCA cycle by condensing with oxaloacetate to form citrate or used in the synthesis of ketone bodies (hence ketogenic) or fatty acids.
Sources: en.wikipedia.org
Molecular dimers are often formed by the reaction of two identical compounds e.g.: 2A → A−A. In this example, monomer "A" is said to dimerize to give the dimer "A−A". Dicyclopentadiene is an asymmetrical dimer of two cyclopentadiene molecules that have reacted in a Diels-Alder reaction to give the product. Upon heating, it "cracks" (undergoes a retro-Diels-Alder reaction) to give identical monomers:
Bill Rosenberg opened the Open Kettle in 1948, a restaurant selling doughnuts and coffee in Quincy, Massachusetts (a suburb of Boston), but in late May 1950, he changed the name to Dunkin' Donuts after discussions with company executives. He conceived the idea for the restaurant after his experiences selling food in factories and at construction sites, where doughnuts and coffee were the two most popular items. The company introduced its first logo in 1953, and the mascot Dunkie in 1954. The restaurant was successful, and Rosenberg sold franchises to others starting in 1955. It was during this time that Johnny Spartos, one of the men running the original Quincy location, convinced Rosenberg to produce a donut with a handle specifically for dunking into a cup of coffee.
== Distribution == Rotheca myricoides is native to mountains from Eritrea to South Africa. It is native to Angola, Botswana, Burundi, Caprivi Strip, Democratic Republic of the Congo, Djibouti, Eswatini, Eritrea, Ethiopia, Kenya, KwaZulu-Natal, Malawi, Mozambique, Namibia, Northern Provinces, Rwanda, Somalia, Sudan, Tanzania, Uganda, Zambia, and Zimbabwe. It was introduced to Trinidad-Tobago, Australia, and Brazil.
Nickel(II) forms compounds with all common anions, including sulfide, sulfate, carbonate, hydroxide, carboxylates, and halides. Nickel(II) sulfate is produced in large amounts by dissolving nickel metal or oxides in sulfuric acid, forming both a hexa- and heptahydrate useful for electroplating nickel. Common salts of nickel, such as chloride, nitrate, and sulfate, dissolve in water to give green solutions of the metal aquo complex [Ni(H2O)6]2+. The four halides form nickel compounds, which are solids with molecules with octahedral Ni centres. Nickel(II) chloride is most common, and its behavior is illustrative of the other halides. Nickel(II) chloride is made by dissolving nickel or its oxide in hydrochloric acid. It is usually found as the green hexahydrate, whose formula is usually written NiCl2·6H2O. When dissolved in water, this salt forms the metal aquo complex [Ni(H2O)6]2+. Dehydration of NiCl2·6H2O gives yellow anhydrous NiCl2. Some tetracoordinate nickel(II) complexes, e.g. bis(triphenylphosphine)nickel chloride, exist both in tetrahedral and square planar geometries. The tetrahedral complexes are paramagnetic; the square planar complexes are diamagnetic. In having properties of magnetic equilibrium and formation of octahedral complexes, they contrast with the divalent complexes of the heavier group 10 metals, palladium(II) and platinum(II), which form only square-planar geometry. Nickelocene has an electron count of 20. Many chemical reactions of nickelocene tend to yield 18-electron products.
=== Scotland to England in 1988 === On 1 May 1988, he set off again from John o' Groats, this time walking through the West Highlands, down the Pennine Way and then south to Land's End: a distance of 1,100 miles (1,800 km) in seven weeks. As part of the training for this walk he ran the gruelling Snowdonia Marathon, in a time of 4 hours and 40 minutes. The walk through Scotland and England raised £2,000 for Macmillan Cancer Support.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.